Scientific evidence suggests that some of the patients with COVID-19 have excessive inflammation, which needs to be addressed immediately to avoid risks of developing further complications. According to a study published in the journal The Lancet , colchicine, an anti-inflammatory drug primarily used to treat gout, can reduce the risks of developing COVID-19 complications. The study was a randomized, double-blinded, placebo-controlled, multi-centric trial conducted on 4488 community-treated COVID-19 patients.
Patients diagnosed with COVID-19 either by RT-PCR testing or clinical criteria, above 40 years of age, and with at least one risk factor for the disease progression were included in the study. The participants were equally assigned to two groups: one group received orally administered colchicine (0.5 mg twice per day for 3 days followed by once per day for 27 days) and the other…
